Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age
Authors:
- S. BlackSBS. Black
- N.P. KleinNKN.P. Klein
- J. ShahJSJ. Shah
- L. BedellLBL. Bedell
- A. KarstenAKA. Karsten
- P.M. DullPDP.M. Dull
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Reconsideration of the Use of Meningococcal Polysaccharide VaccineThe Pediatric Infectious Disease Journal, 2007
- Meningococcal VaccinesCurrent Pharmaceutical Design, 2007
- Conquering the MeningococcusFEMS Microbiology Reviews, 2007
- Recent trends in meningococcal epidemiology and current vaccine recommendationsCurrent Opinion in Pediatrics, 2006
- Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of AgeInfection and Immunity, 2005
- Meningococcal immunologyImmunology and Allergy Clinics of North America, 2003
- Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysisBMJ, 2003
- Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccinationThe Lancet, 2002
- Vaccines Against Polysaccharide AntigensCurrent Drug Targets - Infectious Disorders, 2001
- Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in QuebecJAMA, 2001